Editorial review
Educational content is reviewed for source quality, clinical boundaries, and readability. It is not medical advice; confirm care decisions with a licensed clinician.
How Quickly Does Ketamine Work? It Depends on the Route
Ketamine onset time by route of administration is one of the most practically important distinctions in ketamine pharmacology. Intravenous (IV) delivery produces perceptible effects in roughly 30 seconds. Oral ketamine, by contrast, may take up to 30 minutes before effects begin. Between those extremes sit intramuscular, intranasal, and subcutaneous routes—each with a distinct bioavailability profile, onset window, and required level of clinical supervision.
Understanding why these differences exist—and what they mean in a clinical setting—can help you have more informed conversations with a licensed clinician who knows your full medical history. This page is an educational reference, not a guide for choosing or adjusting treatment on your own.
For a broader overview of how each delivery form is used in practice, see our ketamine treatment methods guide.
Four Concepts That Shape Onset Time
Bioavailability
The fraction of a dose that reaches systemic circulation in active form. IV delivers 100%; oral delivers roughly 20–30% after first-pass liver metabolism.
First-Pass Metabolism
Oral and rectal routes pass through the liver before entering the bloodstream, converting much of the ketamine to its metabolite norketamine and reducing the effective dose.
Absorption Surface
Nasal mucosa, muscle tissue, and subcutaneous fat absorb ketamine at different rates, producing different time-to-peak-plasma curves for each route.
Norketamine
The primary metabolite of ketamine retains roughly 20–30% of the parent drug's activity. Routes with more first-pass conversion tend to produce a higher norketamine-to-ketamine ratio in plasma.
Why Route Matters Beyond Speed Alone
Onset speed is one variable, but it interacts with bioavailability, duration, and the supervision required to monitor a patient safely. A route with a fast onset in a setting without adequate monitoring may not be clinically appropriate even if it is pharmacologically effective. Conversely, a slower-onset oral route may be practical for certain supervised outpatient protocols precisely because its gradual absorption curve is easier to manage.
According to a pharmacokinetic review by Mion and Villevieille (2013), ketamine's lipophilicity and high hepatic extraction ratio explain why parenteral routes bypass the first-pass effect that so substantially reduces oral bioavailability. The drug's hepatic elimination clearance—estimated between 1,000 and 1,600 ml/min, approaching total liver blood flow—means it is metabolized rapidly regardless of route. What differs sharply by route is how much of the drug reaches the brain before that conversion occurs.
Ketamine is also approximately 10–30% protein-bound in plasma and has a distribution volume of around 2.3 L/kg, meaning it distributes widely into tissue. These properties influence peak intensity and duration across routes, not just how fast effects begin.
Compare evidence and options
Compare ketamine with other treatment paths using neutral explainers.
Compare optionsIntravenous Ketamine: Fastest Onset, Most Studied
The intravenous route delivers ketamine directly into the bloodstream, producing 100% bioavailability and the fastest onset of any common delivery method. Analgesic effects can begin within approximately 30 seconds of a bolus dose. For depression-focused protocols, IV ketamine is typically administered as a slow infusion over 40–45 minutes at subanesthetic doses, which changes the experiential onset but keeps bioavailability at its maximum.
Because IV administration bypasses every absorption barrier, clinicians have precise control over the plasma concentration curve. This also means adverse effects—including dissociation, cardiovascular changes, and perceptual disturbances—can appear rapidly. IV ketamine therefore requires continuous clinical monitoring and cannot be self-administered.
IV remains the most-studied route for treatment-resistant depression, and most landmark randomized controlled trial data comes from IV protocols. For more on the historical development of ketamine's psychiatric use, see our ketamine history timeline.
Intramuscular Ketamine: High Bioavailability, Moderate Onset
Intramuscular (IM) injection produces an estimated bioavailability of approximately 93%, the second highest among common routes. Analgesic onset typically occurs within about 5 minutes. Because IM bypasses the first-pass hepatic metabolism of oral routes, the fraction of the nominal dose reaching the brain is substantially higher than oral delivery achieves at the same administered amount.
In clinical settings, IM ketamine is sometimes used when IV access is difficult or when a slightly slower, more gradual onset is preferred. Research reviewed by Cohen et al. (2018) described IM protocols using doses of 0.25–0.5 mg/kg for depression, with researchers noting outcomes that appeared comparable to IV at equivalent doses for certain patient groups. Larger IM doses are sometimes divided into two administrations 15–20 minutes apart to manage peak plasma concentrations.
Duration of effect after IM administration is generally 0.5–2 hours depending on dose and indication. Like IV, IM ketamine carries risks that require a medical setting with monitoring capacity.
Intranasal Ketamine: Moderate Bioavailability, One FDA-Approved Option
Intranasal delivery—including both compounded racemic ketamine and the FDA-approved esketamine nasal spray (Spravato)—produces bioavailability in the range of 45–50%. Onset of effect typically begins within 5–15 minutes, and duration can extend up to approximately 3 hours depending on dose and formulation.
The intranasal route is notable because it is the only route with an FDA-approved ketamine-related formulation for a psychiatric indication. Esketamine (Spravato) received FDA approval in 2019 for treatment-resistant depression and, in a separate formulation, for major depressive disorder with acute suicidal ideation or behavior. It is dispensed only through a Risk Evaluation and Mitigation Strategy (REMS) program, which requires patients to self-administer the drug under observation in a certified healthcare setting and remain monitored for at least two hours after each dose. The FDA REMS database provides current program requirements.
Racemic ketamine administered intranasally—used off-label—has a different pharmacological profile from esketamine. Research including work by Lapidus et al. (2014) explored intranasal racemic ketamine at subanesthetic doses for depression with preliminary positive findings, though the evidence base remains smaller than for IV. The 45–50% bioavailability means a higher nominal dose is required to approach plasma levels achievable with IV or IM routes.
Ketamine Route Comparison: Onset, Bioavailability, and Duration
| Feature | Typical Onset | Typical Duration | Setting Required |
|---|---|---|---|
| Intravenous (IV) | 100% | ~30 seconds (bolus) | Up to 10 min (bolus); longer with slow infusion |
| Intramuscular (IM) | ~93% | ~5 minutes | 0.5–2 hours |
| Intranasal | ~45–50% | 5–15 minutes | Up to 3 hours |
| Oral | ~20–30% | ~30 minutes | 4–6 hours |
| Subcutaneous (SC) | Near-complete | Up to 30 minutes | Variable; often used as continuous infusion |
Oral Ketamine: Lowest Bioavailability, Longest Duration
Oral ketamine has the lowest bioavailability of the commonly used routes—approximately 20–30%—because a substantial portion of the absorbed dose is converted to norketamine during first-pass hepatic metabolism before reaching systemic circulation. Onset typically begins around 30 minutes after ingestion, and the duration of effect is longer than parenteral routes, generally in the range of 4–6 hours.
The longer duration and lower peak plasma concentration characteristic of oral delivery have led some researchers to suggest that the norketamine metabolite may play a proportionally larger role in oral ketamine's effects compared to IV. This remains an area of active investigation rather than settled pharmacology.
Research reviewed by Schoevers et al. (2016) and others explored oral ketamine as an adjunct treatment in treatment-resistant depression, with some studies using doses around 1 mg/kg taken multiple times per week. Oral ketamine has no FDA approval for psychiatric use; any such use is off-label and requires a valid prescription and active medical oversight. For context on who may be considered for ketamine therapy, see our resource on candidacy for ketamine treatment.
Subcutaneous Ketamine: Near-Complete Bioavailability, Gradual Onset
Subcutaneous (SC) delivery involves administering ketamine into the tissue just beneath the skin. Bioavailability is considered near-complete, as the drug absorbs steadily into surrounding capillaries without first-pass metabolism. Onset is slower than IV or IM—up to approximately 30 minutes—but SC infusion is often used continuously at low rates in palliative or chronic pain settings where a sustained steady-state plasma concentration is more clinically useful than a rapid peak.
Research summarized by Quibell et al. (2011) and others describes SC ketamine as generally better tolerated than IV or IM in certain populations, with a tolerability profile that some researchers characterize as favorable for patients requiring ongoing symptom management. Case series have reported SC use for depression at low doses, though the evidence base for psychiatric indications via this route is substantially smaller than for IV or intranasal.
As with all routes, SC ketamine requires clinical oversight and individualized dosing decisions. For related reading on how ketamine is used in pain contexts, see our chronic pain resource.
Educational Reference, Not Medical Advice
Onset times, bioavailability ranges, and duration figures in this article are drawn from published pharmacokinetic research and clinical reviews. Individual responses vary based on body weight, liver function, genetics, concurrent medications, and other factors a clinician must evaluate. Only a licensed medical provider who knows your complete history can determine whether any form of ketamine is appropriate for you. If you are experiencing a mental health crisis or thoughts of self-harm, contact the 988 Suicide and Crisis Lifeline by calling or texting 988, or go to your nearest emergency department.
What Onset Differences Mean When Talking with a Clinician
Knowing the onset profile of each route helps you understand why a clinician might recommend a particular setting or monitoring protocol. A fast-onset route like IV is pharmacologically precise but requires immediate access to trained staff who can respond to adverse effects. A slower-onset route like oral may sound more accessible, but lower bioavailability means the pharmacological exposure is different, and the clinical evidence base for specific indications is less extensive.
Questions worth raising with your prescribing clinician include: Which route is recommended for my situation, and why? What monitoring is in place during and after administration? How does the chosen route's onset and duration fit my schedule and treatment goals? What adverse effects should I watch for, and what is the response plan if they occur?
Route choice is also influenced by regulatory status. Esketamine (Spravato) has a defined REMS framework and FDA approval for specific diagnoses; other routes and formulations are used off-label under individual prescriber judgment. Understanding this distinction helps you evaluate what safeguards are built into a given treatment setting. Our comparison of ketamine versus traditional antidepressants offers further context on where ketamine fits within a broader treatment landscape.
Keep Reading Method Guides
Compare ketamine routes, formulations, and clinical contexts in our method guides before discussing treatment options with your clinician.
Frequently Asked Questions
Intravenous (IV) ketamine has the fastest onset of any common route. Analgesic effects can begin within approximately 30 seconds of a bolus dose because the drug enters the bloodstream directly, bypassing all absorption steps. IV also delivers 100% bioavailability, the highest of any route. This speed and precision come with requirements for continuous clinical monitoring that no other route demands to the same degree.
Oral ketamine must be absorbed through the gastrointestinal tract and then pass through the liver before reaching systemic circulation—a process called first-pass metabolism. The liver converts a substantial portion of the ketamine to its metabolite norketamine during this step, reducing bioavailability to approximately 20–30% and delaying onset to around 30 minutes. The drug that ultimately reaches the brain is a different mix of ketamine and norketamine than what IV delivers at an equivalent nominal dose.
Intranasal esketamine (Spravato) typically produces effects within 5–15 minutes, slower than IV ketamine's bolus onset of roughly 30 seconds. Bioavailability through the nasal mucosa is approximately 45–50%, compared to 100% for IV. Spravato is FDA-approved for specific psychiatric diagnoses and is dispensed only through a REMS program that requires in-facility self-administration under observation, followed by at least two hours of monitoring after each dose.
Bioavailability is the fraction of an administered dose that reaches systemic circulation in an active form. It matters because a lower-bioavailability route requires a higher nominal dose to achieve comparable plasma concentrations—and the mix of ketamine versus its metabolite norketamine in circulation may differ. IV ketamine has 100% bioavailability; intramuscular approximately 93%; intranasal approximately 45–50%; and oral approximately 20–30%. These differences influence dosing decisions, expected onset, peak intensity, and duration of effect for each route.
Yes. IV bolus effects may last up to roughly 10 minutes, while a full slow IV infusion protocol produces a longer clinical session. Intramuscular effects typically last 0.5–2 hours. Intranasal effects can extend up to approximately 3 hours. Oral ketamine has the longest duration—generally 4–6 hours—partly because its slower, lower-peak absorption curve produces a more gradual concentration profile. Subcutaneous infusion duration depends on the infusion rate and total dose administered.
Norketamine is the primary metabolite of ketamine, formed mainly through N-demethylation in the liver. It retains approximately 20–30% of ketamine's pharmacological activity. Norketamine has a longer half-life than ketamine itself, which may contribute to the extended duration seen with oral delivery, where first-pass metabolism produces a relatively higher proportion of norketamine in circulation from the outset. Researchers continue to study norketamine's specific contributions to ketamine's antidepressant and analgesic effects.
Subcutaneous ketamine has been described in some research contexts and case reports for depression, but the published evidence base is substantially smaller than for IV or intranasal routes. SC delivery is more commonly reported in palliative care and chronic pain settings, where slow continuous infusion is practical for sustained symptom management. Any psychiatric use would be off-label and would require individual clinical oversight and prescribing judgment.
Route selection is a clinical decision made by your prescribing physician based on your diagnosis, medical history, available monitoring resources, and the evidence base for each route with your specific indication. You can—and should—ask your clinician to explain their reasoning. Understanding onset, bioavailability, and supervision requirements for each route helps you participate meaningfully in that conversation, but the final decision requires medical expertise and knowledge of your individual clinical picture.
Share
Contact Ketamine Resource
Send corrections, partnership questions, or advertising inquiries.